anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Gastric cancer (GC) is one of the most malignant cancers worldwide. Metabolism disorder is a critical characteristic of malignant tumors related to tumor progression and metastasis. However, the expression and molecular mechanism of malic enzyme 3 (ME3) in GC are rarely reported. In this study, we aim to investigate the molecular mechanism of ME3 in the development of GC and to explore its potential value as a prognostic and therapeutic target in GC.
METHOD: ME3 mRNA and protein expression were evaluated in patients with GC using RT-qPCR, WB, and immunohistochemistry, as well as their correlation with clinicopathological indicators. The effect of ME3 on proliferation and metastasis was evaluated using Cell Counting Kit-8 (CCK-8), 5-ethynyl-20-deoxyuridine (EdU) assay, transwell assay, wound healing assay, and subcutaneous injection or tail vein injection of tumor cells in mice model. The effects of ME3 knockdown on the level of metabolites and hypoxia-inducible factor-1α (HIF-1α) protein were determined in GC cells. Oxidative phosphorylation was measured to evaluate adenosine triphosphate (ATP) production.
RESULTS: ME3 was downregulated in human GC tissues (P < 0.001). The decreased ME3 mRNA expression was associated with younger age (P = 0.02), pathological staging (P = 0.049), and lymph node metastasis (P = 0.001), while low ME3 expression was associated with tumor size (P = 0.048), tumor invasion depth (P < 0.001), lymph node metastasis (P = 0.018), TNM staging (P < 0.001), and poor prognosis (OS, P = 0.0206; PFS P = 0.0453). ME3 knockdown promoted GC cell malignancy phenotypes. Moreover, α-ketoglutarate (α-KG) and NADPH/NADP+ ratios were reduced while malate was increased in the ME3 knockdown group under normoxia. When cells were incubated under hypoxia, the NADPH/NADP+ ratio and α-KG decreased while intracellular reactive oxygen species (ROS) increased significantly. The ME3 knockdown group exhibited an increase in ATP production and while ME3 overexpression group exhibited oppositely. We discovered that ME3 and HIF-1α expression were negatively correlated in GC cells and tissues, and proposed the hypothesis: downregulation of ME3 promotes GC progression via regulating intracellular oxidative stress and HIF-1α.
CONCLUSION: We provide evidence that ME3 downregulation is associated with poor prognosis in GC patients and propose a hypothesis for the ME3 regulatory mechanism in GC progression. The present study is of great scientific significance and clinical value for exploring the prognostic and therapeutic targets of GC, evaluating and improving the clinical efficacy of patients, reducing recurrence and metastasis, and improving the prognosis and quality of life of patients.
The present invention concerns a platinum (II) four-coordinant complex having the formula:   <IMAGE>   wherein R1 is an alkyl diamine or cycloalkyl diamine and R2 and R3 are an alkylcarboxylato containing from five to ten carbon atoms. The R1 is preferably trans-D,L-1,2-diaminocyclohexane, trans-R,R-1,2-diaminocyclohexane, trans-S,S-1,2-diaminocyclohexane, cis-1,2-diaminocyclohexane ethylene diamine or 1,1-bis(aminomethyl)cyclohexane. The R2 and R3 are preferably neohexanoato, neoheptanoato, neononanoato, neodecanoato, neooctanoato, neopentanoato, 2-ethylhexanoato, 2-ehtylbutyrato, 2-propylpropanoato, 2-methyl-2-ethylheptanoato, 2,2-diethylhexanoato, 2,2-dimethyl-4-ethylhexanoato, 2,2-diethyl-4-methylpentanoato, 2,2-dimethyloctanoato, 2-methyl-2-ethylheptanoato, 2,2-diethylhexanoato, 2,2-diethyl-4-methylpentanoato or 2,2,4,4-tetramethylpentanoato. In an important further aspect, the present invention involves preparation and therapeutic use of a liposome comprising a phospholipid and a four-coordinate platinum complex having the formula:     <IMAGE>  wherein R1 is an alkyl diamine or cycloalkyl diamine and R2 and R3 are an alkylcarboxylato containing from about five to about fourteen carbon atoms. The R1, R2 and R3 functions are preferably as described above with the exception that R2 and R3may have even longer alkyl chains such as myristate and laurate, i.e., up to fourteen carbon atoms. For therapeutic use, a pharmaceutical composition comprising this liposome and a pharmaceutically acceptable carrier or diluent may be readily prepared by methods well known to those skilled in the art. The liposomes are useful vehicles for solubilizing the otherwise aqueously insoluble complexes of the present invention. The phospholipids of the liposomes may be one or more of phosphatidylglycerol, phosphatidylcholine, sphingomyelin, phosphatidic acid or phosphatidylserine. The liposomes more preferably consist essentially of phosphatidylglycerol, phosphatidylcholine or a combination thereof and may also comprise cholesterol. The liposomes of the present most preferably comprise phospholipid consisting essentially of dimyristoylphosphatidylglycerol, dimyristoylphosphatidylcholine or a combination thereof.
Central centrifugal cicatricial alopecia (CCCA) is a scarring alopecia of multifactorial etiology that presents on the vertex as patchy areas of hair loss, spreading centrifugally over the scalp. It most commonly affects women of African descent, but cases among other ethnicities have also been reported. CCCA typically starts with thinning and breaking of the hair as the first sign of presentation, which eventually progresses to hair loss over the central part of the scalp, spreading symmetrically outwards to involve a larger area. Currently, there is no definitive cure for the disease; however, multiple management options are available, which should aim to be tailored to the individual patient. Owing to its cosmetic outcomes, the quality of life (QoL) of patients with central centrifugal cicatricial alopecia is also disturbed, as patients may face psychological and social stress due to their permanent hair loss. This article focuses on various aspects of the pathogenesis, clinical trials, quality of life, barriers faced by patients, and treatment of central centrifugal cicatricial alopecia.
FIELD: cosmetics. SUBSTANCE: invention relates to gels used for shaving. The shaving gel composition comprises amine salts of a mixture of lauric, myristic and palmitic acids being the weight ratio of myristic to lauric and palmitic acid is from 2.5 to 3.75:1:1. The composition comprises also sugar and carboxylic acid ester with length of alkyl chain from 8 to 18 carbon atoms, ethoxylated agent with softening and improving slipping properties, ethoxylated alkylglycoside diacid ester comprising alkyl group with from 8 to 18 carbon atoms and cellulose gel-forming substance. Shaving gel exhibits good lubricating property being without skin irritating adverse effect. EFFECT: improved and valuable cosmetic properties of composition. 20 cl, 2 ex
Magnifying endoscopy(ME) uses Narrow Band Imaging (NBI)+ME to observe the non atrophic area of the gastric fundus gland. According to the proportion of the opening of the gastric fundus gland duct in one magnified field of view, it is classified as grade 1 ≤ 25%, indicating Hp current infection, 25%\<grade 2\<50%, Hp uncertain state, indicating Hp current infection or after recent sterilization, grade 3 ≥ 50%, indicating Hp non-infection or past H. pylori infection.
Embodiments of the present disclosure pertain to formulations for cancer treatment that include a particle loaded with diethylstilbestrol (DES) and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may also be loaded into the particle. The formulations may also include a stabilizer that is also loaded into the particle. The particles may be dispersed in an aqueous solution to form a nanosuspension that is adapted for subcutaneous administration and sustained release of DES. Additional embodiments pertain to methods of treating cancer in a subject by administering to the subject a formulation of the present disclosure. The subject may be a human suffering from prostate cancer. The administration of the formulations to the subject may bypass or minimize first pass metabolism. The administration may also minimize hepatic exposure of DES. Additional embodiments pertain to methods of making the formulations of the present disclosure by loading a particle with DES.
In a process for the production of minute oil-containing capsules by coacervation of one of two hydrophilic colloids at least one of which is gellable on to oil droplets dispersed in an aqueous sol of colloid material according to the main Specification, the oil has dissolved therein ethyl cellulose which, during the process, forms a liquid and vapour-impermeable film between the oil droplet and the encapsulating colloid material.  The resulting capsules may be gelled, e.g. by cooling, hardened, e.g. by treatment with formalin and separated from the system, e.g. by filtration, centrifugation or spray-drying.  The oil may be a vegetable, animal or mineral oil or a synthetic oil, e.g. trichlorodiphenyl or methyl salicylate.  Specified colloids are gelatin, gum arabic, albumin. alginates, casein, agar, starch, pectins and Irish moss which, if used in pairs are selected so that a negative and amphoteric colloid are used together.
Patients are currently advised to refrain from driving motor vehicles or using public transportation unescorted for a 24 hour period if they undergo any minor ambulatory surgical procedure with monitored anesthesia care (MAC).However, recently introduced short-acting anesthetics may facilitate rapid recovery and an early return to normal daily activities. The proposed study will compare newer short-acting anesthetic agents (propofol, benzodiazepine, opioid) utilized in MAC, to determine if a particular pharmacological agent, or a combination of agents, impair driving performance as evaluated by driving simulator assessment, at time of discharge from the ambulatory center after minor surgical procedures.The three critical measures of driving performance selected are: weaving, reaction time, and number of collisions. If any of the experimental MAC conditions shows statistical equivalence at discharge with baseline, for all three criterion measures, then that anesthetic regimen can be designated as "safe to drive". If this study can demonstrate such an early recovery of driving ability, which is probably the most complex and dangerous activity commonly encountered, this begs the re-examination of all post-operative activity restrictions imposed on this patient population. Subjects will be grouped as patients with chronic pain undergoing procedures and those without chronic pain undergoing procedures.Subjects with pain issues will be randomized with either 1)Midazolam + Sufentanil + Propofol or 2)Midazolam + Sufentanil. There will be a third group of subjects who are controls not undergoing any procedures.
Methods and systems for managing healthcare cost are disclosed. A method includes receiving, one or more employee preference inputs from an employee for accessing medical services. The one or more employee preference inputs include at least one medical service and location of the employee. The method includes accessing, a plurality of pricing from plurality of medical service providers in predefined region of the location. The method includes accessing, a reward program selected by an employer. The reward program includes at least reward reference percentage and a savings share percentage. The method includes determining, a reference pricing for the at least one medical service based on the reward reference percentage and the median pricing. The method includes determining, differential pricing for each medical service provider by comparing with a corresponding pricing offered. Thereafter, the method includes calculating, reward incentive based on the differential pricing and the saving share percentage.
OBJECTIVES: This study aimed to identify symptom clusters in lung cancer patients undergoing chemotherapy and the central and bridge symptoms within each symptom cluster.
METHODS: In this cross-sectional study, 1,255 patients with lung cancer were recruited through convenience sampling at Nanfang Hospital. Patient symptom burden was assessed using the M.D. Anderson Symptom Inventory (MDASI) and the Lung Cancer module of the MDASI (MDASI-LC). Symptom clusters were identified using the Walktrap algorithm, and central and bridge symptoms in the symptom clusters were identified by network analysis.
RESULTS: The patients included 818 (65.18%) males and 437 (34.82%) females with a mean age of 56.56 ± 11.78 years. Four symptom clusters were identified: fatigue, gastrointestinal, psychoneurological and respiratory. Their central symptoms were fatigue, vomiting, distress and hemoptysis, respectively, and their bridge symptoms were pain, vomiting, dry mouth and shortness of breath.
CONCLUSIONS: Lung cancer symptoms show certain strong correlations with each other, resulting in symptom clusters. Central symptoms may influence other symptoms within a symptom cluster, and bridge symptoms might impact the density of the symptom network. This study identified central and bridge symptoms in lung cancer patients undergoing chemotherapy. Targeting these symptoms with interventions for symptom clusters could make symptom management more precise and effective.
IMPLICATIONS FOR NURSING PRACTICE: In clinical settings, the burden of symptom clusters may be reduced by intervening against the central symptoms of these symptom clusters. Alternatively, if the objective is to diminish the connections between different symptom clusters and holistically alleviate the overall burden, interventions focused on bridge symptoms may be employed.
Patients recovering from COVID-19 commonly exhibit cognitive and brain alterations, yet the specific neuropathological mechanisms and risk factors underlying these alterations remain elusive. Given the significant global incidence of COVID-19, identifying factors that can distinguish individuals at risk of developing brain alterations is crucial for prioritizing follow-up care. Here, we report findings from a sample of patients consisting of 73 adults with a mild to moderate SARS-CoV-2 infection without signs of respiratory failure and 27 with infections attributed to other agents and no history of COVID-19. The participants underwent cognitive screening, a decision-making task, and MRI evaluations. We assessed for the presence of anosmia and the requirement for hospitalization. Groups did not differ in age or cognitive performance. Patients who presented with anosmia exhibited more impulsive alternative changes after a shift in probabilities (r =  - 0.26, p = 0.001), while patients who required hospitalization showed more perseverative choices (r = 0.25, p = 0.003). Anosmia correlated with brain measures, including decreased functional activity during the decision-making task, thinning of cortical thickness in parietal regions, and loss of white matter integrity. Hence, anosmia could be a factor to be considered when identifying at-risk populations for follow-up.
Patients of 70 years and elder with an advanced ovarian cancer who are scheduled to start a maintenance therapy with PARP inhibitors for the first time. The PARP inhibitors are administrated according to the marketing authorization and will be Olaparib (which may by administrated in combination with Bevacizumab) and Niraparib. There is no specific medical visit for this study, patient are followed in a routine care. Some medical data about the disease follow-up will be collected at inclusion and at each visit, every 3 months over a 12-months period. Furthermore, two quality of life surveys (OV28 and ELD14) and one geriatric assessment will be performed at each visit every 3 months and one 8ml-blood sample will be done at inclusion, and after 6 and 12 months of PARP inhibitors treatment.
Risk Summary

Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. There are no available human data informing the risk of embryo-fetal toxicity. In animal models, the PD-1/PD-L1 signaling pathway is important in the maintenance of pregnancy through induction of maternal immune tolerance to fetal tissue (see Data). Human IgG4 (immunoglobulins) are known to cross the placenta; therefore, pembrolizumab has the potential to be transmitted from the mother to the developing fetus. Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

Animal reproduction studies have not been conducted with KEYTRUDA to evaluate its effect on reproduction and fetal development. A literature-based assessment of the effects of the PD-1 pathway on reproduction demonstrated that a central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. Blockade of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering KEYTRUDA during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 knockout mice. Based on its mechanism of action, fetal exposure to pembrolizumab may increase the risk of developing immune-mediated disorders or of altering the normal immune response.
This report describes a unique case of thoracic vertebral canal stenosis and vertebral instability in a 1 yr old Minuet cat. The cat presented with a history of chronic progressive nonambulatory paraparesis. Myelography with neutral and stress positions revealed dynamic compression at T1-4. Computed tomography and MRI revealed multiple sites of vertebral endplate osteolysis, adjacent bone sclerosis, intervertebral disk space narrowing, and spondylotic bridging within the cervical and cranial thoracic vertebral bodies and pedicles, particularly at C6-T4. The cat underwent a right-sided T1-4 hemilaminectomy and C7-T4 vertebral stabilization using positively threaded profile pins and polymethylmethacrylate. The cat fully recovered without any complication. The case highlights the potential for young cats, especially those with a chondrodysplastic condition, to develop vertebral canal stenosis and vertebral instability. The surgical treatment described herein resulted in an excellent outcome.
Compositions and methods for treating skin redness. According to an embodiment, the invention is a topical skin care composition having a dermatologically acceptable vehicle, such as, water and a plurality of ingredients dissolved in the vehicle. The ingredients include: a blend of natural oils; a plurality of vitamins; and 0.1-1 wt % salicyloyl phytosphingosine. The composition is unsuitable for application on the eyelids or eye area. The blend of natural oils includes: aloe barbadensis leaf juice extract; cocos nucifera (coconut oil); hydrolyzed glycosaminoglycans; and caprylic/capric triglycerides. The plurality of vitamins is selected from a group consisting of vitamin C, vitamin E, salts/derivatives of vitamin C and vitamin E, and mixtures thereof. In one aspect, the plurality of vitamins includes: sodium ascorbyl phosphate; disodium lauriminodipropionate tocopheryl phosphate; and jojoba oil.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to preparing agent used for treatment of rhinitis. Agent comprises a base and hydrophilic compounds taken among the group: polyethylene glycol, glycerol, carboxymethylcellulose, copolymers of acrylic acid taken in the amount 0.99 g per 1 g of agent. Agent comprises additionally antiseptic preparations taken among the group: zinc sulfate, dioxydin boric alcohol, liquor Burovi (aluminum acetate basic solution), hydrogen peroxide; antibiotics with broad spectrum of effect taken in the amount 0.0001-0.1 g per 1 g of medium; immunomodulating agents taken among the group: recombinant alpha-, beta-, gamma-interferon taken in the amount 1000-20 000 IU per 1 g of medium; antiviral preparations taken among the group: essential oils, kalanchoe juice, onion juice, garlic juice taken in the amount 0.01-0.05 g per 1 g of medium. As essential oils the agent comprises fir oil, tea tree oil, gum- -tree oil, mint oil. Agent comprises additionally silver- containing component: colloidal silver of silver nitrate; anti-inflammatory preparations taken among the group: diclofenac sodium, indometacin, ibuprofen, naproxen; preparations eliciting proteolytic activity: acetylcysteine or trypsin, and vitamins also. As a base the agent comprises one or some components among additions including glycerol, polyethylene oxide, castor oil, oleic acid, vegetable oil, essential oil. Invention provides the development of highly effective agents used for treatment of rhinitis. EFFECT: valuable medicinal properties of agent. 9 cl, 5 ex
Transdermal plaster (A) containing progesterone A-specific ligands (I) as active substance, comprises a back layer, at least a coupling, active substance containing adhesive layer (based on e.g. silicone polymer) and a removable protective film, where the concentration of the active substance is 0.1-10%, related to the total weight of the adhesive matrix. Transdermal plaster (A) containing progesterone A-specific ligands of formula (I) or their derivatives or descendants as active substance, comprises a back layer, at least a coupling, active substance containing adhesive layer (based on silicone polymer, polyisobutylene polymer, polyacrylate polymers or styrol block copolymer with butadiene or isoprene) and a removable protective film, where the concentration of active substance is 0.1-10%, related to the total weight of the adhesive matrix. R 1, R 2H or F; R 3CH 3 or CF 3; and Ar : 4-methyl-benzo[d][1,2]oxazin-1-one-6-yl or 3H-isobenzofuran-1-one-5-yl. An independent claim is also included for the preparation of (I). [Image].
For the exercise group, subjects were asked to follow a simple walking regimen. Walk normally with stable and comfortable stride rates during their exercise. The duration and frequency was initiated at a 30-minute or more daily exercise at least five days per week and gradually increased to a maximum of 60 minutes within subject's comfort zone.
A method of treatment employing cardiac glycoside is disclosed. A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.